SC15: DEVELOPMENT OF BIOASSAYS FOR CHECKPOINT IMMUNOTHERAPY AND OTHER IMMUNO-ONCOLOGY LEADS
Room Location: 105
SUNDAY, MARCH 10 | 5:30 - 8:30 PM
ABOUT THIS COURSE:
During the last years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. Early evaluation of the effectiveness of candidate therapeutics and combination therapies can be done using and in vitro bioassays with primary mouse or human immune cells. These can be used to evaluate the functionality of check-point blockers, the effect of molecules on macrophages and myeloid derived suppressor cells and regulatory T cells.
TOPICS TO BE COVERED INCLUDE:
- Developing a functional bio-assay from scratch
- Handling primary immune cells
- What do the data tell us?
- Challenges and pitfalls
- Examples and case studies
Sofie Pattijn, CTO, ImmunXperts
Sofie Pattijn (CTO and founder, ImmunXperts) has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.
Back To Short Courses